Close menu
  • News
  • Products
  • Contact
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
    • 3 News in Focus
    • 5 Business & Money
    • 5 Science & Tech
    • 5 Lifestyle & Health
    • 0 Policy & Public Interest
    • 1 People & Culture
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
    • Overview
    • Distribution by PR Newswire
    • Cision IR
    • SocialBoost
    • All Products
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
    Close submenu (News in Focus)News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
    Close submenu (Business & Money)Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
    Close submenu (Science & Tech)Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
    Close submenu (Lifestyle & Health)Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
    Close submenu (Policy & Public Interest)Policy & Public Interest
    Close submenu (People & Culture)People & Culture
    • People & Culture
    Accessibility Statement Skip Navigation
    • Resources
    • Blog
    • Journalists
    • Log In
    • Sign Up
    • Data Privacy
    • Send a Release
    Return to PR Newswire homepage
    • News
    • Products
    • Contact
    When typing in this field, a list of search results will appear and be automatically updated as you type.

    Searching for your content...

    No results found. Please change your search terms and try again.
    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • All Automotive & Transportation
        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • All Business Technology
        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • All Entertain­ment & Media
        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertain­ment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • All Financial Services & Investing
        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • All General Business
        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • All Consumer Technology
        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • All Energy
        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • All Environ­ment
        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environ­ment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • All Heavy Industry & Manufacturing
        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • All Telecomm­unications
        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecomm­unications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • All Consumer Products & Retail
        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • All Entertain­ment & Media
        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertain­ment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • All Health
        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • All Sports
        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • All Travel
        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • All Policy & Public Interest
        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • All People & Culture
        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

        • In-Language News

        • Arabic
        • español
        • português
        • Česko
        • Danmark
        • Deutschland
        • España
        • France
        • Italia
        • Nederland
        • Norge
        • Polska
        • Portugal
        • Россия
        • Slovensko
        • Suomi
        • Sverige
    • Overview
    • Distribution by PR Newswire
    • Cision IR
    • Guaranteed Paid Placement
    • SocialBoost
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    Labcorp Announces Expansion of Precision Oncology Portfolio to Support Pharmaceutical, Biopharma, and Clinical Research in Advancing Drug Development Programs

    Labcorp Logo (PRNewsfoto/Labcorp)

    News provided by

    Labcorp

    Apr 08, 2024, 07:00 ET

    Share this article

    Share toX

    Share this article

    Share toX

    Portfolio expansion solidifies company's commitment to advancing cancer research and patient care

    BURLINGTON, N.C., April 8, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the strategic expansion of its precision oncology portfolio, solidifying its commitment to advancing cancer research and patient care on a global scale. The announcement underscores Labcorp's dedication to investing in scientific, diagnostic and laboratory innovations to support its pharmaceutical, biotechnology and clinical research partners in bringing groundbreaking therapies to market.

    Labcorp continues to demonstrate its leadership in precision oncology by expanding its portfolio of solutions that support the development of novel therapies for oncology with the launch of its proprietary platform for molecular residual disease (MRD), Labcorp® Plasma Detect™, enhancement of its circulating tumor DNA (ctDNA) genomic profiling solution Labcorp® Plasma Complete™, and continued investment in expanding its capabilities in cell and gene therapy.

    "Labcorp is at the forefront of the evolution of precision oncology, expanding the understanding and application of biomarkers, enabling innovative technologies and platforms to deliver improved genomic profiling solutions, and delivering solutions designed to improve patient outcomes," said Dr. Brian Caveney, Labcorp's chief medical and scientific officer. "Our portfolio expansion enhances our integrated services to empower our partners with the solutions and support they need to advance their development programs and make a lasting difference in patients' lives."

    Introducing Labcorp Plasma Detect
    Labcorp recently announced the commercial availability of Labcorp Plasma Detect, the first clinically validated, tumor-informed, whole-genome sequencing circulating tumor DNA (ctDNA) MRD solution for research and investigational use. This powerful solution identifies patients at an increased risk of recurrence after surgery or adjuvant chemotherapy (ACT) and is extensible to clinical applications and can help enhance patient outcomes through rapid, reliable analysis. Labcorp Plasma Detect validation data will be presented at the American Association for Cancer Research (AACR) annual meeting on April 9 in San Diego, California.

    Enhancing Labcorp Plasma Complete
    Labcorp Plasma Complete, a comprehensive next-generation sequencing (NGS)-based ctDNA genomic profiling assay, has been enhanced with matched analysis of white blood cells that enables identification of germline variants and clonal hematopoietic (CH) variants that confound most ctDNA-based profiling approaches. This research assay enables the identification of clinically relevant variants across 521 genes, including SNVs, indels, bTMB, MSI, LOH, and select amplifications and translocations.

    Expanded Capabilities in Cell and Gene Therapy and Development of Antibody Drug Conjugates 
    Labcorp's deep scientific expertise and comprehensive solutions include specialized pre-clinical discovery, biomarker and companion diagnostics (CDx) development and post-commercialization capabilities. Within this development-to-commercialization continuum, cell and gene therapy is a growing focus of biopharma pipelines, with more than 2,000 clinical trials in cell and gene therapy globally representing approximately 20% of all biopharma drugs in the pipeline and a total global investment of $11.7 billion.

    Today, Labcorp supports 100% of FDA-approved CAR T-cell therapies and more than 85% of all gene replacement therapies. Further, and with the growing interest in antibody-drug conjugates as cancer therapeutic agents to improve targeting to tumor cells, Labcorp has supported collaborations and programs that have led to 87% of approved antibody drug conjugates (ADCs), 76% of which are indicated for advanced clinical stages.

    Labcorp's deep scientific, regulatory and market access expertise and substantial reach into various patient populations through an expansive diagnostic testing portfolio positions it as the laboratory partner of choice for this transformative area of medicine, enabling the acceleration of novel, advanced, and targeted therapy development, rapidly advancing patient care from day one post-approval and beyond.

    To learn about Labcorp's oncology solutions, visit https://oncology.labcorp.com/biopharma-partners.

    About Labcorp
    Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's more than 67,000 employees serve clients in approximately 100 countries, provided support for 84% of the new drugs and therapeutic products approved in 2023 by the FDA, and performed more than 600 million tests for patients around the world. Learn more about us at www.labcorp.com.

    SOURCE Labcorp

    WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

    icon3
    440k+
    Newsrooms &
    Influencers
    icon1
    9k+
    Digital Media
    Outlets
    icon2
    270k+
    Journalists
    Opted In
    GET STARTED

    Modal title

    Also from this source

    Labcorp Launches H5 Bird Flu Test in the U.S., Now Available for Order through Physicians

    Labcorp Launches H5 Bird Flu Test in the U.S., Now Available for Order through Physicians

    Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the commercial availability of its new H5...

    Labcorp Expands Sexually Transmitted Infection (STI) Test Offerings with Rapid Syphilis Test

    Labcorp Expands Sexually Transmitted Infection (STI) Test Offerings with Rapid Syphilis Test

    Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it has expanded its portfolio of sexually...

    More Releases From This Source

    Explore

    Health Care & Hospitals

    Health Care & Hospitals

    Medical Pharmaceuticals

    Medical Pharmaceuticals

    Biotechnology

    Biotechnology

    Pharmaceuticals

    Pharmaceuticals

    News Releases in Similar Topics

    Contact PR Newswire

    • Call PR Newswire at 888-776-0942
      from 8 AM - 9 PM ET
    • Chat with an Expert
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices

    Products

    • For Marketers
    • For Public Relations
    • For IR & Compliance
    • For Agency
    • For Small Business
    • All Products

    About

    • About PR Newswire
    • About Cision
    • Become a Publishing Partner
    • Become a Channel Partner
    • Careers
    • Accessibility Statement
    • Asia
    • APAC
    • APAC - Traditional Chinese
    • Brazil
    • Canada
    • Czech
    • Denmark
    • Finland
    • France
    • Germany
    • India
    • Indonesia
    • Israel
    • Korea
    • Italy
    • Japan
    • Mexico
    • Middle East
    • Middle East - Arabic
    • Netherlands
    • Norway
    • Poland
    • Portugal
    • Russia
    • Slovakia
    • Spain
    • Sweden
    • United Kingdom

    My Services

    • All New Releases
    • Online Member Center
    • ProfNet

    Do not sell or share my personal information:

    • Submit via Privacy@cision.com 
    • Call Privacy toll-free: 877-297-8921

    Contact PR Newswire

    Products

    About

    My Services
    • All News Releases
    • Online Member Center
    • ProfNet
    Call PR Newswire at
    888-776-0942
    • Terms of Use
    • Privacy Policy
    • Information Security Policy
    • Site Map
    • RSS
    • Cookie Settings
    Copyright © 2025 Cision US Inc.